Patents by Inventor Mark Hamann

Mark Hamann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kahalalide-producing bacteria
    Publication number: 20070196901
    Abstract: Disclosed are strains of Vibrio sp bacteria that produce kahalalides or derivatives thereof, methods of isolating said strains, and 16S rRNA sequences useful in identifying kahalalides producing bacteria.
    Type: Application
    Filed: November 1, 2004
    Publication date: August 23, 2007
    Inventors: Russell Hill, Julie Enticknap, Karumanchi Rao, Mark Hamann
  • Manzamine-producing actinomycetes
    Publication number: 20050244938
    Abstract: Disclosed are strains of actinomycetes that produce manzamines or derivatives thereof, methods of isolating said strains, and a 16S rRNA useful in identifying manzamine-producing bacteria.
    Type: Application
    Filed: August 1, 2003
    Publication date: November 3, 2005
    Applicants: University of Maryland Biotechnology Institute, University of Mississippi
    Inventors: Russell Hill, Olivier Peraud, Mark Hamann, Noer Kasanah
  • Manzamines in the treatment of infectious disease
    Publication number: 20050159400
    Abstract: A method of treating an infectious disease or condition in a subject in need of such treatment is disclosed. The method comprises administering to a subject an effective amount of a manzamine, manzamine derivative or analog or an optical isomer or racemate or tautomer thereof or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 5, 2005
    Publication date: July 21, 2005
    Inventors: Mark Hamann, Khalid El-Sayed
  • Methods of treating disease through the administration of a manzamine analog or derivative
    Publication number: 20050085554
    Abstract: A method of treating cancer, inflammatory disease or an infectious disease or condition in a subject in need of such treatment is disclosed. The method comprises administering to a subject an effective amount of a manzamine, or a rationally modified manzamine derivative or analog or an optical isomer or racemate or tautomer thereof or a pharmaceutically acceptable salt or prodrug thereof generated through optimized fermentation of a Micromonospora sp., extraction from sponges and then modified through semisynthesis.
    Type: Application
    Filed: June 28, 2004
    Publication date: April 21, 2005
    Inventors: Mark Hamann, Karumanchi Rao, Jiangnan Peng